Please assess the completion status of the following clinical trial:

Trial Title: Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Has Type 2 diabetes mellitus~* Has inadequate glycemic control on diet/exercise therapy and sitagliptin monotherapy~* Hemoglobin A1C (HbA1c) ≥7.0% and ≤10.0% before study participation~Exclusion Criteria:~* History of type 1 diabetes mellitus or a history of ketoacidosis~* History of any of the following medications: Thiazolidinediones (TZD) and/or insulin within 12 weeks prior to study participation, sodium glucose cotransporter 2 (SGLT2) inhibitors anytime~* Currently has a urinary tract infection or genital infection with subjective symptom

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ipragliflozin (Type: EXPERIMENTAL): Ipragliflozin one 50 mg tablet co-administered with one 50 mg sitagliptin once daily (QD) for 52 weeks in addition to diet and exercise therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).